Navigation Links
AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
Date:4/30/2009

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its first quarter 2009 financial and operating results before market open on Wednesday, May 6, 2009. The Company will host a conference call and webcast to discuss these results later that same day at 3:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-644-3422, 514-807-8791 or 800-587-1893. A replay of the webcast will also be available on the Company's website for a period of 30 days.

The Company further announced that it will hold its Annual Shareholder Meeting also on Wednesday, May 6, 2009 starting at 10:30 a.m. Eastern Time, in Rooms 6 and 7 of the Centre Sheraton Montreal Hotel, 1201 Rene-Levesque Boulevard West, in Montreal.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
2. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
3. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
4. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
5. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
6. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
7. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
9. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:9/1/2014)... NewYork (PRWEB) September 01, 2014 ... Biotech and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading life ... understand and analysis of how and why companies ... of a prospective partner’s negotiated deals terms provides ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... ... the availability of two new atomic force microscope (AFM) probes types with carbon nanotube ... CNT probes offer quantum improvements for AFM imaging, substantially improving results, reducing overall cost ... ...
... FRANCISCO, Calif., June 16 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment of ... Executive Officer of Sunesis, will be presenting at the Jefferies ... New York on June 17, 2009. , , The ...
... 16 Three Rivers Pharmaceuticals announced today positive results ... Efficacy of Combined Therapy (DIRECT) clinical trial authored by ... , and colleagues at 44 centers in the United ... (SVR), was achieved demonstrating that INFERGEN provides a second ...
Cached Biology Technology:Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 2Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 2Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 4
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... your integrity? Tell the truth; everyone has a tipping point. ... we,ll lie if the benefit is great enough. Now, scientists ... make that decision. , The result was published online ... "We prefer to be honest, even if lying is beneficial," ... associate at the Virginia Tech Carilion Research Institute , ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2
... Calif. UC Riverside,s Alexander Raikhel , a professor ... National Academy of Sciences (NAS) for his excellence in ... is one of the highest honors given to a scientist ... inducted into the academy next April during its 147th annual ...
... the 61st Annual Meeting of the Rocky Mountain Section ... May 2009 in Orem, Utah. Utah Valley University ... building on the UVU campus. Brigham Young University is ... industry scientists, and graduate and undergraduate students, will highlight ...
... million in U.S. dollars have been awarded to ... studies related to asthma and other immune system ... extramural grants were awarded by the Biomedical Research ... and Research), the government agency driving Singapore,s transformation ...
Cached Biology News:UC Riverside professor receives top scientific honor 2UC Riverside professor receives top scientific honor 3Geoscientists meet to discuss Rocky Mountain geology 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 3Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 4
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Biology Products: